MRD
Showing 1 - 25 of 1,776
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Not yet recruiting
- C-KIT Mutation
- (no location specified)
Nov 2, 2023
AML, Adult, Minimal Residual Disease Trial (MRD assessment)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- MRD assessment
- (no location specified)
Oct 13, 2023
NSCLC Trial in Beijing
Recruiting
- NSCLC
-
Beijing, ChinaYuyan Wang
Oct 10, 2023
MRD Test in Common Risk Stage II Colorectal Cancer
Not yet recruiting
- Stage II Colorectal Cancer
- MRD test
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xian Jiaotong University
Mar 29, 2023
Renal Cell Carcinoma Trial in Birmingham (Pembrolizumab injection)
Not yet recruiting
- Renal Cell Carcinoma
- Pembrolizumab injection
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 20, 2023
MRD Detection by NGS in Pediatric B-ALL
Completed
- Acute Lymphoblastic Leukemia, Pediatric, Next Generation Sequencing
- MRD
-
Hangzhou, Zhejiang, ChinaThe Children's Hospital of Zhejiang University School of Medicin
Jul 25, 2023
Non-invasive MRD Assessment in Multiple Myeloma
Recruiting
- Myeloma
- MRD Assessment
-
New York, New YorkNew York Presbyterian Hospital/Columbia University Irving Medica
Nov 15, 2022
AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- chidamide and azacitidine
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Sep 27, 2023
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction
Not yet recruiting
- Non-small Cell Lung Cancer
- NGS and ctDNA-MRD detection
-
Changsha, Hunan, ChinaDepartment of Thoracic Surgery, Second Xiangya Hospital of Centr
Apr 18, 2023
Cervical Cancer Trial in Suzhou (Chemoradiotherapy + Adjuvant chemo and Zimberelimab, Chemoradiotherapy (small pelvic) +
Recruiting
- Cervical Cancer
- Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
- Chemoradiotherapy (small pelvic) + Zimberelimab
-
Suzhou, Jiangsu, ChinaThe Affiliated Suzhou Hospital of Nanjing Medical University
May 14, 2023
Early-stage Breast Cancer Trial in Beijing, Langfang (The MRD strategy for high risk or MRD+ TNBC patients, The MRD strategy for
Recruiting
- Early-stage Breast Cancer
- The MRD strategy for high risk or MRD+ TNBC patients
- +5 more
-
Beijing, Beijing, China
- +2 more
Apr 21, 2022
Rectal Cancer Patients Based on ctDNA-MRD Technology
Recruiting
- Rectal Adenocarcinoma
- +3 more
- MRD detection
-
Guangzhou, Guangdong, ChinaWeiWei Xiao
Jul 31, 2023
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)
Recruiting
- B-Cell Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
-
Tampa, FloridaMoffitt Cancer Center
Nov 28, 2023
Clinical Research of Drug Holiday Based on MRD Detection in GIST
Recruiting
- Gastrointestinal Stromal Tumors
-
Beijing, Beijing, ChinaPeking University People's Hospital
May 11, 2023
Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou
Not yet recruiting
- Minimal Residual Disease
- Esophageal Squamous Cell Carcinoma
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jun 10, 2023
Plasma MRD and cfDNA HPV and Efficacy and Prognosis of Locally
Recruiting
- Locally Advanced Cervical Cancer
- Concurrent chemoradiotherapy
-
Guiyang, Guizhou, ChinaYong Li
Jul 14, 2023
Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)
Recruiting
- Acute Lymphoblastic Leukemia
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023
ctDNA-MRD in Predicting Efficacy of Esophageal Squamous Cell
Not yet recruiting
- Squamous Cell Carcinoma of Esophagus
- (no location specified)
Feb 25, 2023
Lung Cancer Stage III Trial (ctDNA)
Not yet recruiting
- Lung Cancer Stage III
- ctDNA
- (no location specified)
Oct 26, 2023
MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With
Not yet recruiting
- Multiple Myeloma
- Minimal Residual Disease
- (no location specified)
Nov 1, 2023
Postoperative Recurrence in Biliary Tract Cancers:A Multicenter
Recruiting
- Biliary Tract Cancer
- No intervention
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with NanJing Medical University
Feb 15, 2023
ALL, MRD-positive, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Inotuzumab Ozogamicin)
Recruiting
- ALL
- +2 more
- Inotuzumab Ozogamicin
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 14, 2023
Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)
Recruiting
- Multiple Myeloma
- anti-BCMA CAR-T
-
Tianjin, Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
May 4, 2023
MRD Recurrence Monitoring After Surgical Resection of
Not yet recruiting
- HCC
- Liver resection
- (no location specified)
Jul 10, 2022